+検索条件
-Structure paper
| タイトル | Engineered antibodies that stabilize drug-modified KRAS neoantigens enable selective and potent cross-HLA immunotherapy. |
|---|---|
| ジャーナル・号・ページ | Nat Commun, Vol. 16, Issue 1, Page 11264, Year 2025 |
| 掲載日 | 2025年12月17日 |
著者 | Lorenzo Maso / Sarah A Mosure / Sergio A Rodriguez-Aponte / Angelina Pizzo / Diamond N Mensah / Matthew Southard / Samantha Sze / Tanvir Ahmed / Brian Vash / Takamitsu Hattori / Epsa Rajak / Akiko Koide / Benjamin G Neel / Shohei Koide / Weifeng Liu / Sean T Toenjes / Paul Da Silva Jardine / Rajesh Chopra / Christoph Rader / Lauren E Stopfer / ![]() |
| PubMed 要旨 | Covalent inhibitors of oncoprotein KRAS have initial efficacy, but responses lack durability. Covalently modified oncoproteins are presented as MHC-restricted hapten-peptides (p*MHC) on the cancer ...Covalent inhibitors of oncoprotein KRAS have initial efficacy, but responses lack durability. Covalently modified oncoproteins are presented as MHC-restricted hapten-peptides (p*MHC) on the cancer cell surface, enabling combination of targeted therapy with immunotherapy to overcome drug resistance. Building on indirect evidence of KRAS-derived p*MHCs, we use immunopeptidomics to identify and directly quantify these synthetic neoantigens. To address challenges by their low copy number, we develop AETX-R114, a T cell engaging bispecific antibody with picomolar affinity for MHC-restricted sotorasib-modified KRAS peptides presented by three HLA-A3 supertype alleles. AETX-R114 dramatically increases the half-life and thereby the number of presented p*MHCs, enabling selective and potent killing of resistant cancer cells both in vitro and in vivo. To broaden the therapeutic potential of creating and targeting synthetic neoantigens, we further develop AETX-R302, which recognizes divarasib-modified KRAS peptides presented on alleles from the HLA-A2 and A3 supertypes. Cryo-EM structure determination reveals the molecular basis for breaking HLA supertype restriction. Collectively, our study illustrates how engineered antibodies can transform synthetic neoantigens into actionable cancer immunotherapy targets. |
リンク | Nat Commun / PubMed:41408054 / PubMed Central |
| 手法 | EM (単粒子) |
| 解像度 | 2.58 - 3.23 Å |
| 構造データ | EMDB-49361, PDB-9nfb: EMDB-49362, PDB-9nfc: |
| 化合物 | ![]() PDB-1awr: |
| 由来 |
|
キーワード | PROTEIN BINDING / Antibody / Cancer-neoantigen / complex |
ムービー
コントローラー
構造ビューア
万見文献について



著者
リンク




homo sapiens (ヒト)
キーワード